Cyclophosphamide, Methotrexate, and Fluorouracil; Oral Cyclophosphamide; Levamisole; or No Adjuvant Therapy for Patients With High-Risk, Premenopausal Breast Cancer.

The article discusses the 25-year results of Danish Breast Cancer Cooperative Group (DBCG) 77-B trial, which evaluates the efficacy of breast cancer medication therapy such as oral cyclophosphamide and the combination of cyclophosphamide, methotrexate, and fluorouracil (CMF). The study gathered data from 1,146 premenopausal patients with breast cancer and taking cancer medication. The study showed that CMF and cyclophosphamide improved the disease-free survival of the patients for 25 years.